Talphera, Inc.

TLPH Healthcare Drug Manufacturers Specialty & Generic

In the quarter to June 2026, revenue fell 99.6%, EPS grew 40.0% and free cash flow fell 33.1%, each against the same quarter a year earlier. Operating cash flow growth for five consecutive years; insiders bought in the last twelve months.

1.08 0.01 +0.93%
Market cap
$55.5M
P/E
0.0×
Fwd P/E
−3.1×
Dividend yield
—
F-score
n/a
Altman Z
−20.73
Beneish M
n/a
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
ROE
(143.36%) (118.40%) (114.16%) (85.97%)

+8 more TTM periods

ROA
(69.60%) (63.14%) (59.60%) (47.87%)
ROIC
0.00% 0.00% 0.00% 0.00%
Return on Tangible Assets
(109.25%) (82.33%) (83.61%) (66.21%)
Average Days of Receivables
— — — 0.00
Free Cash Flow per Share
(0.16) (0.16) (0.27) (0.27)
Free Cash Flow
(12.27) (11.29) (11.36) (11.18)
Other line items
Cash ROIC
(38.97%) (28.53%) (30.37%) (27.63%)
Accounts Receivable Turnover
— — — 0.00
Accounts Payable Turnover
0.00 0.00 0.00 0.00
Average Days of Payables
0.00 0.00 0.00 0.00
Tax Rate
0.00 0.00 0.00 0.00
Research and Development Expense of Revenue
0.00% 0.00% 0.00% 1,360.33%
Selling, General and Administrative Expense of Revenue
0.00% 0.00% 0.00% 1,704.23%
Share Based Compensation of Revenue
0.00% 0.00% 0.00% 174.65%
Operating CF/Net income
0.81 0.79 0.80 0.90
Depreciation/Fixed assets
0.00 0.00 0.00 0.00
Capex/Depreciation
0.00 0.00 0.00 0.00
Revenue per Share
0.00 0.00 0.00 0.01
Operating CF per Share
(0.16) (0.16) (0.27) (0.27)
Capex per Share
0.00 0.00 0.00 0.00
Capex to Sales
— — — 0.00

Fold the line items

Columns are period end dates